Chris Shibutani
Chris Shibutani
case light needs trying whether
It will take more verdicts to tell whether trying every case individually is sustainable or needs to be revisited in light of plaintiff victories.
time visible
Now is about the right time where he does have to become more visible as a CEO.
amidst attraction growth investors key minded negative outlook pipeline providing shares value
Bristol-Myers' dividend has been an important attraction for value minded investors -- providing the key back-stop for shares even amidst the company's near-term negative growth outlook and lackluster pipeline news.
absorb cash company expect financial future portfolio position product
With Pfizer's diversified product portfolio and cash position that can be used for future deals, we would expect the company to be able to absorb the financial impact,